Search

Your search keyword '"Penza, O."' showing total 17 results
Start Over Author "Penza, O."
17 results on '"Penza, O."'

1. Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998–2000

Author

Migliori, G. B., Fattorini, L., Vaccarino, R., Besozzi, G., Saltini, C., Orefici, G., Iona, E., Matteelli, A., Fiorentini, F., Codecasa, L. R., Casali, Lucio, Cassone, A., De Santis, A., Giorgio, V., Vinciguerra, P., Angarano, G., Petrozzi, L., Costa, D., Gozzellino, F., Perboni, A., Marchetti, D., Pascali, A., Falcone, F., Mariano, V., Rizza, F., Pretto, P., Turano, A., Carosi, G. P., Farris, A. G., Ligia, G. P., Orani, G., Farris, B., Foschi, C., Trucco, G., Aiolfi, S., Ceruti, T., Parpanesi, M., Calabro, S., Felisatti, G., Tortoli, E., Nutini, S., Montini, G., D'Ambrosio, V., Ceraminiello, A., Bernorio, S., Buono, L., Montesano, P., Vinci, E., Sabato, E., Gamba, S., Crepaldi, P., Magliano, E., Penati, V., Vaccarino, P., Astolfi, A., Bertoli, G., Rupianesi, F., Losi, M., Richeldi, L., Ferrara, Giovanni, Minuccio, E., Napolitano, G., Molinari, G. L., Saini, L., Garzone, A., Vertuccio, C., Marcias, S., Menozzi, M., Marone, P., Peona, V., Nascimbene, C., Pasi, A., Cascina, A., Monaco, A., Penza, O., Pasticci, Maria Bruna, Bistoni, F., Sposini, T., Colorizio, V., Confalonieri, M., Bottrighi, P., Macor, G., Moretti, G., Fatigante, R., Barbaro, A., Agati, G., Zaccara, F., Viola, S., Le Donne, R., Farinelli, G., Mancini, D., Ermeti, M., Longi, R., Tronci, M., Bisetti, A., Altieri, A., and Fadda, G.

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Tuberculosis, Prevalence of resistance, Drug Resistance, Antitubercular Agents, Drug resistance, Proficiency testing, Drug, Immigrant, Susceptibility testing, Emigration and Immigration, Humans, Italy, Laboratories, Prevalence, Drug Resistance, Multiple, Bacterial, Tuberculosis, Multidrug-Resistant, Internal medicine, medicine, Ethambutol, business.industry, Public health, Isoniazid, Bacterial, Multidrug-Resistant, medicine.disease, Surgery, Streptomycin, business, Multiple, Rifampicin, medicine.drug
Abstract

In 1998 a network of 20 regional tuberculosis (TB) laboratories (the Italian Multicentre Study on Resistance to Antituberculosis drugs (SMIRA) network) was established in Italy to implement proficiency testing and to monitor the prevalence of drug resistance nationwide. The network managed 30% of all TB cases reported in Italy each year. The aim of the present report is to describe: 1) the accuracy of drug-susceptibility testing in the network; 2) the prevalence of drug resistance for the period 1998-2000. Data were collected from the network laboratories. Sensitivity to streptomycin and ethambutol increased from the first survey (1998-1999) to the second survey (2000) from 87.7 to 91.9%. Specificity, predictive values for resistance and susceptibility, efficiency and reproducibility were consistent in both surveys. In previously untreated cases, the prevalence of multidrug-resistance was the same in both surveys (1.2%), while a slight decrease from the first to the second survey was observed for monoresistance to rifampicin (from 0.8 to 0.4%) and isoniazid (from 2.9 to 2%). The significant association found between isoniazid resistance and immigration is a useful indicator for both clinicians managing individual tuberculosis cases and public health services planning control strategies.

Published
2003

2. EVALUATION OF RISK FACTORS FOR ACUTE BACTERIAL EXACERBATIONS IN COPD PATIENTS

Author

Lo Cicero, Salvatore, Sturkenboom, M, Logroscino, C, Dolcetti, A, Losito, G, Nardini, S, Carone, M, Penza, O, De Benedetto, F, Villa, M, and Mannino, S

Subjects
Lung diseases, Obstructive -- Complications and side effects -- Risk factors, Bacterial infections -- Risk factors -- Complications and side effects, Health, Complications and side effects, Risk factors
Abstract

Salvatore Lo Cicero, MD(*); M Sturkenboom, MD; C Logroscino, MD; A Dolcetti, MD; G Losito, MD; S Nardini, MD; M Carone, MD; O Penza, MD; F De Benedetto, MD; M [...]

Published
2000

8. Surveillance of anti-tuberculosis drug resistance: Results of the 1998/1999 proficiency testing in Italy

Author

Migliori, G. B., Ambrosetti, M., Fattorini, L., Penati, V., Vaccarino, P., Besozzi, G., Ortona, L., Saltini, C., Orefici, G., Moro, M. L., Iona, E., Cassone, A., Santis, A., Giorgio, V., Vinciguerra, P., Angarano, G., Petrozzi, L., Costa, D., Gozzellino, F., Perboni, A., Marchetti, D., Pascali, A., Falcone, F., Mariano, V., Rizza, F., Pretto, P., Turano, A., Alberto Matteelli, Carosi, G. P., Tedoldi, S., Pinsi, G., Farris, A. G., Ligia, G. P., Orani, G., Farris, B., Foschi, C., Trucco, G., Aiolfi, S., Ceruti, T., Parpanesi, M., Calabro, S., Felisatti, G., Tortoli, E., Nutini, S., Montini, G., Fiorentini, F., D Ambrosio, V., Ceraminiello, A., Bernorio, S., Buono, L., Montesano, P., Vinci, E., Sabato, E., Gamba, S., Crepaldi, P., Bertoli, G., Rupianesi, F., Losi, M., Richeldi, L., Ferrara, G., Minuccio, E., Napolitano, G., Molinari, G. L., Saini, L., Garzone, A., Vertuccio, C., Marcias, S., Menozzi, M., Marone, P., Peona, V., Nascimbene, C., Pasi, A., Cascina, A., Casali, L., Monaco, A., Penza, O., Pasticci, M. B., Bistoni, F., Sposini, T., Colorizio, V., Confalonieri, M., Bottrighi, P., Orsi, A., Schiavi, L., Macor, G., Moretti, G., Fatigante, R., Barbaro, A., Agati, G., Zacarra, F., Viola, S., Le Donne, R., Farinelli, G., Mancini, D., and Ermeti, M.

9. Prevalence of resistance to anti-tuberculosis drugs: Results of the 1998/99 national survey in Italy

Author

Giovanni Battista Migliori, Fattorini, L., Vaccarino, R., Besozzi, G., Saltini, C., Orefici, G., Iona, E., Matteelli, A., Fiorentini, F., Codecasa, L. R., Casali, L., Cassone, A., Santis, A., Giorgio, V., Vinciguerra, P., Angarano, G., Petrozzi, L., Costa, D., Gozzellino, F., Perboni, A., Marchetti, D., Pascali, A., Falcone, F., Mariano, V., Rizza, F., Pretto, P., Turano, A., Carosi, G. P., Farris, A. G., Ligia, G. P., Orani, G., Farris, B., Foschi, C., Trucco, G., Aiolfi, S., Ceruti, T., Parpanesi, M., Calabro, S., Felisatti, G., Tortoli, E., Nutini, S., Montini, G., D Ambrosio, V., Ceraminiello, A., Bernorio, S., Buono, L., Montesano, P., Vinci, E., Sabato, E., Gamba, S., Crepaldi, P., Magliano, E., Penati, V., Vaccarino, P., Astolfi, A., Bertoli, G., Rupianesi, F., Losi, M., Richeldi, L., Ferrara, G., Minuccio, E., Napolitano, G., Molinari, G. L., Saini, L., Garzone, A., Vertuccio, C., Marcias, S., Menozzi, M., Marone, P., Peona, V., Nascimbene, C., Pasi, A., Cascina, A., Monaco, A., Penza, O., Pasticci, M. B., Bistoni, F., Sposini, T., Colorizio, V., Confalonieri, M., Bottrighi, P., Macor, G., Moretti, G., Fatigante, R., Barbaro, A., Agati, G., Zaccara, F., Viola, S., Le Donne, R., Farinelli, G., Mancini, D., Ermeti, M., Longi, R., Tronci, M., Bisetti, A., Altieri, A., and Fadda, G.

10. Evaluation of tuberculosis treatment results in Italy, report 1998

Author

Centis, R., Ianni, A., Migliori, G. B., Casali, L., Agati, G., Aiolfi, S., Altieri, A., Ambrosetti, M., Angarano, G., Arossa, W., Bagnasco, G., Bazzerla, G., Berra, A., Besozzi, G., Bottrighi, P., Bugiani, M., Calabro, S., Castiglioni, G., Cavallero, M., Cicchitto, G., luigi codecasa, Colorizio, V., Confalonieri, M., D Ambrosio, L., D Ambrosio, V., Dellatommasa, S., Di Pisa, G., Ermeti, M., Faccini, E., Falcone, F., Farinelli, G., Fatigante, R., Farris, B., Fatur Volante, T., Felisatti, G., Ferranti, P., Fiorentini, F., Foschi, C., Garzone, A., Giorgio, V., Gozzellino, F., Jacopino, L., Lauriello, G., Le Donne, R., Longi, R., Macor, G., Mancini, D., Marchesani, M. F., Marcias, S., Mariano, V., Mennea, G., Monaco, A., Montesano, G., Moretti, G., Napolitano, G., Nardini, S., Nutini, S., Orani, G., Orsi, A., Parpanesi, M., Pasi, A., Penza, O., Perboni, A., Petrozzi, L., Pretto, P., Rossi, S., Sabato, E., Saini, L., Schiavi, L., Tazza, R., Trucco, G., Vertuccio, C., Viviani, U., Volante, M., Vinciguerra, P., Viola, S., Zaccara, F., Barelle, L., Bertoli, G., Bisetti, A., Bistoni, F., Buono, L., Carbonara, S., Carosi, G. P., Cascina, A., Cassone, A., Costa, D., Crepaldi, P., Santis, A., Diamare, F., Fabbro, L., Fadda, G., Farris, A. G., Fattorini, L., Ferrara, G., Gamba, S., Iona, E., and Losi, M.

11. GP management of community-acquired pneumonia in Italy: The ISOCAP study

Author

Sanguinetti, C. M., Benedetto, F., Donner, C. F., Del Prato, B., Fogliani, V., Lorgroscino, C., Mistretta, A., Schito, G., Cacciani, G., GIORGIO WALTER CANONICA, Dolcetti, A., Falcone, F., Lo Cicero, S., Neri, M., Pozzi, E., Schiavina, M., Munafò, G., Parentini, G., Penza, O., Principe, R. S., Saltini, C., Tubaldi, A., Agati, G., Crimi, N., Ferrara, G., Francesca, F., Lsedda, M., Logroscino, C., Mirabella, S., Moretti, A., Picciolo, F., Viola, B., Parola, D., and Zanello, A.

Subjects
Pulmonary and Respiratory Medicine, Pediatrics, medicine.medical_specialty, Community-acquired pneumonia, diagnosis, lcsh:Medicine, Physical examination, remission, medicine, COPD, medicine.diagnostic_test, treatment, business.industry, Mortality rate, Incidence (epidemiology), lcsh:R, medicine.disease, Pneumonia, Concomitant, general practitioner, pulmonary specialist, Ceftriaxone, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

Background. Community-Acquired Pneumonia (CAP) is still a significant problem in terms of incidence, mortality rate, particularly in infants and the elderly, and socioeconomic burden. General Practitioners (GPs) are the first reference for patients with this disease, but there are few published studies regarding the outpatient treatment of CAP. Methods. The ISOCAP study aimed to identify the type and outcome of the diagnostic-therapeutic management of CAP by GPs in Italy, within the framework of developing a closer interrelationship between GPs and pulmonary specialists. Thirty-six Pulmonary Divisions throughout Italy each contacted 5 local GPs who agreed to recruit the first 5 consecutive patients who consulted them for suspected CAP within the study’s 1-year observation period. Results. A total of 183 GPs took part in the study and enrolled, by the end of the observation period, 763 CAP patients; of these, complete data was available for 737 patients [males=373, females=364, mean age (±SD) 58.8±19.6 years]. 64.4% of patients had concomitant diseases, mainly systemic arterial hypertension and COPD. Diagnosis of CAP was based by GPs on physical examination only in 41.6% of cases; in the remaining chest X-ray was also performed. In only 4.6% of patients were samples sent for microbiological analysis. All patients were treated with antibiotics: 76.7% in mono-therapy, 23.3% with a combination of antibiotics. The antibiotic class most prevalently used in mono-therapy was cephalosporin, primarily ceftriaxone; the most frequently used combinations were cephalosporin+macrolide and cephalosporin+quinolone. Mono-therapy was effective in 70% of cases, the combination of two or more antibiotics in 91.2% of patients. Overall treatment efficacy was 94.7%; hospitalisation was required in 8.5% of cases. Conclusions. Outpatient management of CAP by GPs in Italy is effective, hospitalisation being necessary only in the most severe cases due to age, co-morbidities or extent of pneumonia. This signifies a very significant savings in national health costs.

12. Community-acquired pneumonia in adults: a multicentric observational AIPO study.

Author

Logroscino CD, Penza O, Locicero S, Losito G, Nardini S, Bertoli L, Cioffi R, and Del Prato B

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents therapeutic use, Chi-Square Distribution, Community-Acquired Infections drug therapy, Community-Acquired Infections microbiology, Community-Acquired Infections mortality, Comorbidity, Female, Humans, Italy epidemiology, Male, Middle Aged, Pneumonia drug therapy, Pneumonia mortality, Prospective Studies, Risk Factors, Pneumonia microbiology
Abstract

The aim of this study was to obtain reliable data about the current aetiology (i.e. the frequency of the individual pathogens) of community-acquired pneumonia (CAP) while surveying the diagnostic and therapeutic behaviour of Italian chest physicians, compared with existing guidelines, and to test the usefulness of the current severity "criteria" or score as a predictor of disease outcome and guide for appropriate hospitalization. A prospective multicentre observational trial was carried out between October 1994 and February 1996 by the Italian Association of Hospital Pneumologists (AIPO) study group on respiratory infections. A total of 613 consecutive patients suffering from CAP were enrolled in 25 centres throughout Italy. Clinical, radiological and microbiological data were collected and patients were followed-up until complete resolution or death. Aetiological tests were not carried out in 204 patients. In the remaining 409 cases, the aetiology was defined by serological and quantitative microbiological tests in 184 (44.9%) patients. A total of 194 strains of pathogen were detected. The most frequently detected micro-organism was Streptococcus pneumoniae (18.5% of pathogen strains) but, unlike in other series of patients, high percentages of intracellular pathogens (32.5%, all with serological confirmation, mostly due to Chlamydia pneumoniae (13.4%) and of Gram-negative enterobacteria and Pseudomonas aeruginosa (12.5%) were also found. Antibiotic treatment differed from that recommended in American Thoracic Society guidelines, with a greater use of third-generation cephalosporins. Overall, a higher rate of hospitalization and a lower death rate than in other comparable studies was observed.

Published
1999

13. Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer.

Author

Darwish S, Minotti V, Crinò L, Rossetti R, Maranzano E, Checcaglini F, Fiaschini P, Mercati U, Penza O, and Vitali R

Subjects
Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carcinoma, Non-Small-Cell Lung pathology, Chemotherapy, Adjuvant, Cisplatin administration & dosage, Etoposide administration & dosage, Feasibility Studies, Female, Humans, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Pilot Projects, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
Abstract

In an attempt to improve the curative potential of surgery, 46 patients with unresectable Stage IIIA (Clinical N2) non-small cell lung cancer received neoadjuvant chemotherapy with cisplatin and etoposide. After 2 or 3 cycles, 45 patients were evaluable for response; the overall response rate was 82% (37/45) with 3 complete and 34 partial responses. Toxicity was primarily hematologic. Surgical exploration was performed on 35 patients, but resection was possible in only 33 (73%). Of these, 28 resections were complete (62%). Four patients (2CR, 2PR; 9%) had no tumor in biopsy specimen. Three deaths were surgery-related. Median survival of the entire 46 patients was 24.5 months with a 2-year survival of 53%. Cisplatin and etoposide is an effective chemotherapeutic regimen for regionally advanced non-small cell lung cancer; the resection and survival rates justify further trials to compare this approach to other treatment modalities.

Published
1994
Full Text
View/download PDF

14. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study.

Author

Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M, Patoia L, Santi E, Penza O, and Ballatori E

Subjects
Female, Humans, Male, Middle Aged, Nausea chemically induced, Nausea prevention & control, Sex Factors, Vomiting chemically induced, Cisplatin adverse effects, Dexamethasone therapeutic use, Metoclopramide therapeutic use, Vomiting prevention & control
Abstract

To prevent delayed emesis induced by cisplatin (mean dose 90 mg/m2), 120 consecutive patients were randomized to receive, in a 7-day crossover design, oral metoclopramide (20 mg q.i.d.), dexamethasone (1 mg q.i.d.) or placebo (two tablets q.i.d.) starting 24 hours after the end of chemotherapy. Complete protection from nausea, but not from vomiting. was significantly increased by both dexamethasone and metoclopramide with respect to placebo. Important prognostic factors favoring the appearance of delayed emesis were incomplete protection from vomiting during the first 24 hours after cisplatin, female gender, and highest cisplatin doses. Tolerability of both drugs was good. Larger and randomized controlled trials are necessary to identify better preventive treatment of delayed emesis induced by cisplatin.

Published
1991
Full Text
View/download PDF

17. [Screening tests for porphyria].

Author

Del Favero A, Abbritii G, and Penza O

Subjects
Humans, Mass Screening, Methods, Porphyrias classification, Porphyrias etiology, Occupational Medicine, Porphyrias diagnosis
Published
1973

Catalog

Books, media, physical & digital resources
See catalog results